MAIA Biotechnology (MAIA)

Executive Summary

MAIA Biotechnology is a clinical-stage oncology company developing THIO, a first-in-class telomere-targeting agent that induces cancer cell death and stimulates a durable anti-tumor immune response. The company’s lead candidate, THIO, is being evaluated in combination with the PD-1 inhibitor cemiplimab for non-small cell lung cancer (NSCLC), a large and underserved market. MAIA has advanced THIO into a Phase 2 trial (NCT05208944) and a pivotal Phase 3 trial (NCT06908304) in NSCLC, the latter initiated in late 2025. Additionally, the company is exploring ategansoline (another telomere-targeting agent) in combination with cadonilimab for resectable hepatocellular carcinoma in a Phase 1 study (NCT07446257). With a market capitalization of approximately $80 million, MAIA represents a high-risk, high-reward opportunity in the immuno-oncology space. The company’s unique mechanism of action, which directly targets telomeres to trigger cancer cell death and enhance immune recognition, differentiates it from conventional checkpoint inhibitors and chemotherapy. If successful, THIO could become a backbone therapy for multiple solid tumors. However, the early-stage nature of the pipeline and the competitive landscape in NSCLC warrant cautious optimism. MAIA’s progress over the next 12–18 months will be critical in validating its technology and driving shareholder value.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 THIO + cemiplimab interim data in NSCLC40% success
• Q3 2026Phase 3 THIO combination trial enrollment completion update70% success
• H1 2027Phase 1 ategansoline + cadonilimab initial safety/efficacy data30% success